###### Strengths and limitations of this study

-   Strength 1: This is a randomised controlled two-arm double-blind multicentre trial which provides the first type A evidence concerning the necessity of early energy intake for patients with AP.

-   Strength 2: The study enjoys continuous support from an International Translational Advisory Board (ITAB) including several well established experts.

-   Strength 3: Data will be separately handled by an Independent Data Management Board (IDMB).

-   Strength 4: There are no unknown drugs/therapy used in the study, therefore no adverse and serious adverse events are expected.

-   Limitation 1: In order to detect a treatment effect of at least 50% of the early treatment, a sample size of 957 subjects will be necessary to be recruited which will delay the final conclusion of the study.

-   Limitation 2: The double-blind arrangement of the study requires many staff members working on the project which may limit the number of joining centres.

Background {#s1}
==========

Acute pancreatitis (AP) is an inflammatory disease of the exocrine pancreas which is life threatening in its severe form. Unfortunately, while the overall mortality of AP is around 2--5%, and in its severe form 25--57%, no specific treatment is available. Besides the limited interest of pharmacological companies, the main reasons are (1) the small number of research teams in the field and (2) the lack of collaboration between basic and clinical scientists. Importantly, many new therapeutic targets were identified in the last decade with clear translational merits.[@R1] One of the main highlights among them is the discovery of energy depletion in the early phase of AP.[@R1]

It has been shown that, almost independently of the aetiological factors, the early phase of AP is almost the same. Bile acids, ethanol, fatty acids and the latter's metabolite fatty acid ethyl esters cause mitochondrial damage and ATP depletion in pancreatic ductal and acinar cells, driving the cells to death and causing pancreatic necrosis.[@R1] Very importantly, restoration of ATP levels in both cell types prevented cell death and at least partially restored their function.[@R1] In experimental pancreatitis models the same observations have been revealed.[@R10] Although these experimental observations clearly suggest that restoration of the energy level could be a therapeutic tool in AP, this has not been translated into clinical trials.

One of the best and most physiological way of delivering energy to a patient is enteral nutrition (EN). Not surprisingly, besides fluid resuscitation this is almost the only way to significantly reduce mortality in AP.[@R22] Recent analyses of prospectively collected data from 600 patients with AP showed that the mortality is 27% with EN and 57% without EN in the severe form (SAP).[@R34] Importantly, EN decreases mortality but also reduces the frequency of multiorgan failure and the need for interventions in patients with SAP.[@R35] No data are available on whether early or on-demand nutrition/energy supply is beneficial in SAP. The recently published Dutch PYTHON study suggests that there is no difference between early and on-demand enteral tube feeding in SAP, but patients may have received an insufficient amount of energy at the early phase of the disease.[@R36] In the early EN group, patients received over 20 kcal/kg/day only from day 3 onwards whereas, in the on-demand group, they received energy supplementation only from day 6.[@R37] In mild and moderate AP (MAP) much less information is available concerning the usefulness of EN. There is a large variety of protocols on EN in MAP. Immediate oral feeding,[@R38] nasojejunal feeding[@R39] and nasogastric feeding[@R42] have all been used. Notably, immediate oral feeding significantly decreased the length of hospital stay.[@R38] Early (within 24 hours) nasogastric EN was well tolerated and reduced the intensity and duration of abdominal pain, decreased the necessity for opiates and almost completely eliminated the risk of oral food intolerance.[@R42] In order to obtain stronger evidence of the usefulness of early EN in MAP and SAP, we performed a systematic review and meta-analysis which showed that early EN can be beneficial in both MAP and SAP.[@R35] However, we also realised the lack of multicentre randomised control trials addressing energy intake in the early phase of AP.

The main objective of this trial is to determine whether early energy supplementation is beneficial to patients with AP. Our hypothesis is that early energy supplementation will prevent the cells from death or decrease the size of necrosis if it occurs. This will decrease the systemic immune response that will result in a lower frequency of multiorgan failure and mortality. To prove this concept, a randomised clinical trial involving all patients with AP is needed.

Methods {#s2}
=======

Design {#s2a}
------

This is a randomised controlled two-arm double-blind multicentre trial. Patients with AP will be randomly assigned to groups A (high energy administration starting within 24 hours of hospital admission) and B (no energy administration after 24 hours of hospital admission).

Trial organisation, committees and boards {#s2b}
-----------------------------------------

GOULASH is designed and coordinated by the Centre for Translational Medicine at the University of Pécs and the Hungarian Pancreatic Study Group (HPSG). HPSG was established in 2011 in order to stimulate research in pancreatic diseases. To date, HPSG has published the relevant guidelines of pancreatic diseases in order to improve patient care in the field of pancreatology[@R44] and has initiated four prospective clinical trials (EASY, PREPAST, APPLE and PINEAPPLE).[@R48]

The following committees and boards will be involved:

### Steering committee (SC) {#s2b1}

The Steering committee (SC) will be led by PH (gastroenterologist, internal medicine specialist). The members will be KM (medical doctor, full time employee on the project), ÁV (gastroenterologist, internal medicine specialist), ZM (intensive care specialist), TM (clinical research specialist), AS (multidisciplinary unit specialist), MP (gastroenterologist, internal medicine specialist), NF (radiologist), DK (surgeon) and IB (interventional radiologist). SC will make decisions concerning all relevant questions including the drop-outs during the study.

### International translational advisory board (ITAB) {#s2b2}

The committee will include a gastroenterologist (MML), a surgeon (JPN) and basic scientists (MST, OHP). ITAB will continuously monitor the progress of the study and will give advice to the SC.

The study was designed by the SC and ITAB. The study is financially sponsored by the University of Pécs, the Hungarian Academy of Sciences and the National Research, Development and Innovation Office. Neither sponsors were involved in the design of the study, and they will have no access to the database management or to the randomisation code.

Study population {#s2c}
----------------

All patients diagnosed with AP will be informed of the possibility of taking part in the GOULASH study. After the consent form is signed, a computer using a block randomisation protocol will randomise the patients ([figure 1](#F1){ref-type="fig"}).

![Flow chart of participants according to the SPIRIT 2013 statement.[@R53]](bmjopen-2017-015874f01){#F1}

### Inclusion criteria {#s2c1}

The inclusion criteria are: (1) patients over 18 years of age; (2) diagnosed AP on the base of the '2 out of 3' criteria of the IAP/APA guideline[@R52]: (a) upper abdominal pain; (b) serum amylase or lipase \>3x upper limit of normal range; (c) characteristic findings on pancreatic imaging; however those patients without abdominal pain will be excluded because the onset of AP cannot be determined; (3) signed written informed consent form.

### Exclusion criteria {#s2c2}

The exclusion criteria are: (1) hospitalisation 72 hours before admission; (2) abdominal pain \>120 hours (5 days); (3) delirium tremens; (4) Child-Pugh C stage liver cirrhosis; (5) AP due to malignancy; (6) already on artificial nutrition (EN or PN); (7) pregnancy; (8) BMI \>40 or \<18; (9) age \>80 years; (10) ketoacidosis; and (11) whenever CT with contrast is contraindicated.

Sample size {#s2d}
-----------

Sample size calculation was based on the Hungarian National Registry operated by the HPSG. Our recent analyses indicated that multiorgan failure existing for more than 48 hours arises in 9%, whereas mortality occurs in 2.8% of all patients with AP.[@R34] Altogether they represent around 10% of all AP patients. In order to detect a treatment effect of at least 50% of the early treatment, a sample size of 957 subjects will be necessary to be recruited using a 10% drop-out rate, 80% power and 95% significance level. The calculation was performed by the independent data management and biostatistics provider company (IDMB, Adware Research Ltd, Balatonfüred, Hungary).

Randomisation {#s2e}
-------------

In each centre participants will be divided into two groups receiving one of the two study treatments. The allocation of participants to the different groups will be carried out based on predefined randomisation lists created separately for each recruiting centre. The randomisation lists will be prepared with a block size of 4 and with an allocation ratio of 1:1.

Duration {#s2f}
--------

The planned starting date of the study is 1 January 2017 and the planned finishing date of the study is 1 January 2020.

Blinding {#s2g}
--------

The medical staff (eg, those taking the measurements such as blood pressure, examining health records for events such as abdominal pain, reviewing and interpreting examination results such as X-ray or CT) and the patient receiving the intervention will be blinded to knowledge of treatment assignment. The person providing the intervention cannot be blinded in this study. Sealed envelopes ensure the allocation sequence. Nutritional support equipment will be covered until the fourth day to ensure that only the person who made the randomisation will know into which group the patient was enrolled.

Intervention {#s2h}
------------

Based on the currently available guidelines, enteral feeding can be started at any time for patients with AP. In addition, no calorie restriction/order has been described. Therefore, both groups can be regarded as being treated within accepted practice recommendations.

In this study, early high energy administration will be the intervention. Patients will be randomised to group A or B (see [figure 2](#F2){ref-type="fig"}).

![Schedule of enrolment, interventions and assessments according to the SPIRIT 2013 statement.[@R53] Patients will be randomised to group A (high energy) or B (low energy). Online [supplementary figure 1](#SP1){ref-type="supplementary-material"} Form A contains the parameters collected on admission. Online [supplementary figure 2](#SP2){ref-type="supplementary-material"} Form B contains parameters collected every day during hospitalisation. Online [supplementary figure 3](#SP3){ref-type="supplementary-material"} Form C contains parameters collected 1 month after hospital discharge.](bmjopen-2017-015874f02){#F2}
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### Groups {#s2h1}

In group A, high energy will be delivered after admission. Patients will receive a 10 Ch nasogastric (NG) or nasojejunal (NJ) feeding tube on admission. EN will be immediately started as follows: on day 0 (from admission until the start of EN, which can vary from 2 to 24 hours): calorie intake will be 0 kcal/kg/day; from day 1, high energy enteral tube feed 30 kcal/kg/day will be provided until the oral feeding starts. In group B, low energy administration will be delivered after hospital admission. Patients will receive a NG or NJ feeding tube at admission as described above. On day 0 (from admission until the start of EN): calorie intake will be 0 kcal/kg/day; on day 1, 0 kcal/kg/day; on day 2, 10 kcal/kg/day, on day 3, 20 kcal/kg/day and from day 4, 30 kcal/kg/day will be delivered until the oral feeding starts. However, between groups A and B only the amount of calories administered will be different. Patients will receive the same amount of fluid and ions during EN (see below).

Ingredients of enteral tube feed: high energy enteral tube feed (100 mL) {#s2i}
------------------------------------------------------------------------

### Energy {#s2i1}

150 kcal (630 kJ), protein 6 g (16%E), carbohydrate 18.3 g (49%E), fat 5.8 g (35%E) + minerals: 134 mg sodium, 201 mg potassium, 108 mg calcium, 108 mg phosphorus, 34 mg magnesium, 100 mg chloride (0%E). In this study we will use Nutrison Energy (Numil Ltd, Budapest, Hungary), which is a registered product in Hungary (reg. number: 1217).

Zero energy enteral tube feed (100 mL) {#s2j}
--------------------------------------

### Energy {#s2j1}

0 kcal (0 kJ), protein 0 g, carbohydrate: 0 g, fat 0 g + minerals: 134 mg sodium, 201 mg potassium, 108 mg calcium, 108 mg phosphorus, 34 mg magnesium, 5.562 g chloride (0%E). In this study the local institutional pharmacy will provide it in accordance with the Hungarian regulations. Whenever 10 or 20 kcal/kg/day calories are to be delivered, a mixture of the abovementioned two solutions will be used.

### Type of enteral tube {#s2j2}

Patients neither vomiting nor having gastric fluid retention \>250 mL will receive a NG tube. Patients either vomiting or having gastric fluid retention \>250 mL will receive a NJ tube (placement will be done either endoscopically or radiologically). In case of Glasgow Coma Score (GCS) 14 or lower in a patient who is not intubated, the NG tube will be replaced by a NJ tube (risk of aspiration). Abdominal X-ray will be used to check the position of the tube.

Start of mixed feeding (around 2620 kcal): 1000 mL tap water distributed for 24 hours and 300 g (around 1900 kcal) biscuits/toasts/low fat meal (containing at least 75% carbohydrate) orally plus enteral tube feed (480 mL, 720 kcal/day) will be started on the day when: (1) abdominal pain has ceased for at least 6 hours before the new day started; (2) the C-reactive protein (CRP) level has started decreasing; and (3) the amylase or lipase level has started decreasing.

Start of total feeding (around 2000 kcal): if the patient has no symptoms during the mixed oral/enteral feeding and the CRP, amylase or lipase levels are not rising again, total feeding (according to local policy) can be started.

### Other issues {#s2j3}

The speed of EN will be different for patients depending on the body weight, however, the maximum speed of EN cannot exceed 65 mL/hour. In case of difficulties reaching an intake of 30 kcal/kg/day calories (if the patient's body weight is \>75 kg), additional intravenous calories will be added using Sterofundin G. A maximum of 2000 mL (400 kcal) can be delivered in this way. If NG feeding is not tolerated, the NG tube will be replaced by a NJ tube as described above. If NJ feeding is not tolerated, EN will be reduced by 50% and increased again gradually until tolerated. If the re-increasing process is still not tolerated, total parenteral nutrition (TPN) will be started to reach the required energy target. In patients with SAP, TPN must be delivered via a central venous catheter.

Other treatment of subjects {#s2k}
---------------------------

General treatment indicated by the IAP/APA guideline will be utilised.[@R52]

Discharge of patients {#s2l}
---------------------

Uniformisation of the length of hospital stay is necessary to avoid bias concerning length of hospital stay. Readmission within 1 week after discharge has to be considered as the same hospital admission. Patients will be counted as discharged from hospital/from the study when (1) oral feeding is tolerated for 24 hours; (2) amylase/lipase levels are not elevated after total enteral feeding; (3) CRP level is \<50 mg/L; (4) abdominal pain has completely resolved; and (5) no other pancreatitis-related complication requiring hospitalisation is detected.

Endpoints {#s2m}
---------

The following primary endpoints will be calculated: a combination of multiorgan failure for more than 48 hours and mortality. The following secondary endpoints will be analysed: (1) pancreatic necrosis; (2) nutrition-related complications (eg, diarrhoea, aspiration pneumonia, pneumothorax due to central TPN catheter placement); (3) need for conversion from NG to NJ feeding tube; (4) need for conversion from EN to TPN; (5) days until the start of total feeding; (6) use of antibiotics; (7) pain relapse; (8) CRP; (9) white blood cells; (10) procalcitonin; (11) infection; (12) length of hospital stay; (13) need for ICU admission; (14) length of ICU therapy; (15) organ failure; (16) complications; (17) costs calculation. Notably, only direct costs will be calculated that include all medications, services, salaries of healthcare professionals, equipment and day care costs.

Monitored parameters during hospitalisation {#s2n}
-------------------------------------------

There will be a large variety of parameters monitored during the study (eg, medical history, physical examination, laboratory tests, diagnostic imaging, therapy, interventions). Form A will contain the parameters collected on admission (online [supplementary figure 1](#SP1){ref-type="supplementary-material"}). Form B will contain parameters collected every day during hospitalisation (online [supplementary figure 2](#SP2){ref-type="supplementary-material"}). Form C will contain parameters collected 1 month after hospital discharge (online [supplementary figure 3](#SP3){ref-type="supplementary-material"}). For details see supplementary materials or web page (<http://www.pancreas.hu/en/studies/goulash>), which will be available from February 2017. Data collection on the case report form (CRF) will be done electronically (see data management).

Data management and statistical analyses {#s2o}
----------------------------------------

### Data handling {#s2o1}

Data will be handled by the IDMB. Electronic CRF (eCRF) will be used. The Investigator will ensure that the data in the eCRF are accurate, complete and legible. Detailed data flow will be described in a Data Management Plan (DMP). Data from completed eCRFs will be validated under the direction of the Data Manager at IDMB according to a Data Cleaning Plan (DCP). Any missing, implausible or inconsistent recordings in the eCRFs will be referred back to the Investigator using a data query form (DQF), and be documented for each individual subject before clean file status is declared. All changes to eCRFs will be recorded. Before Data Base Lock the Data Review Meeting will decide and document necessary steps related to any issue in the database and define the analysis sets. Members of the Data Review Meeting are a delegated investigator, biostatistician and data manager. Adverse events will be coded using MedDRA (AdWare Research Ltd), who will act as IDMB, works according to GCP, GLP, FDA 21CFR PART11 and other relevant regulatory requirements. AdWare Ltd.has GLP and ISO 9001 certificates.

### Study populations {#s2o2}

Three analysis populations will be defined:

Safety Analysis Set (SAS): all patients enrolled in the study.

Per Protocol Set (PPS): all enrolled patients who finished the study conforming to the requirements of the study protocol.

Intention to Treat (ITT): all randomised participants who start on a treatment, excluding consent withdrawals.

### Withdrawal of a subject from PPS {#s2o3}

Any participants/investigators and the IDMB can submit recommendations for dropouts from the PPS group with reasons given to the SC. All recommendations will be filed. The SC will discuss all the information and, if the alteration in the protocol would be expected to have any bearing on the interventions and outcomes of the study, the patient will not be included in the final per-protocol analysis. Automatic dropout from the per-protocol group shall be ordered if: (1) any of the exclusion criteria are diagnosed during the course of AP; (2) at least 50% of the energy requirement is not achieved on any days during the study; (3) parameters required for answering the primary endpoints are missing; or (4) serious medical reasons not related to pancreatitis occur (eg, accidents, stroke).

### Applied software {#s2o4}

Statistical analysis will be performed using SAS 9.2 or SPSS 19 (or later) statistical packages; Microsoft MS Word will be used for reporting.

### Statistical methods {#s2o5}

Baseline patient and disease characteristics will be analysed using descriptive analysis. Demographic and baseline characteristics will be summarised for the overall study population. Continuous variables will be described by mean, median, SD and ranges and categorical variables will be described by absolute and relative frequencies. A graphical presentation of efficacy variables will be prepared, if applicable. Descriptive statistics for both the primary and secondary parameters will be analysed similarly. Mean changes (with 95% CI) from baseline to end-of-study visit will also be presented. χ^2^tests will be applied to compare proportions between the different groups. Mortality/extended multiorgan failure will be investigated using the Kaplan--Meier analysis method, while subgroup comparisons will be performed using the χ^2^ or Fisher's exact test, as appropriate. For safety data, descriptive statistics and individual listings of adverse events will also be presented.

### Subgroups {#s2o6}

The following subgroups will be made during statistical analyses: (1) ages (\<40 years, 40--59 years, 60--80 years); (2) BMI (\<20, 20--24, 25--29, 30--35, \>35); (3) start of abdominal pain before admission (≤24 hours, 24--48 hours, ≥48 hours); (4) severity of the disease SAP and MAP. In all subgroup analyses, aetiologies will be done descriptively. No confirmatory statistical testing will be applied. Hence, statistical tests and p values attached to them will be regarded as descriptive and not as tests of hypotheses.

Details of the applied statistical tests will be described in the Statistical Analysis Plan.

Early quality assessment {#s2p}
------------------------

Early quality assessment check will be performed on the first 100 patients. The IDMB (AdWare Ltd) will perform an independent assessment of the trial-related documents and activities, with the aim of ensuring the respect of subjects' rights, safety and well-being and to guarantee the plausibility of the clinical data. The similarity of the groups at baseline will also be checked. The IDMB will report to the SC. The SC will discuss all the information and, if the differences would be expected to have any bearing on the interventions and outcomes of the study or the overall dropout rate from PPS is \>20% of all participants who were randomised or allocated into each group or the differential dropout rate is \>15% between the arms, the study needs to be reassessed and the IDMB will make recommendations regarding either re-evaluation of power calculation, extension of recruitment period, extension of number of study centres or termination of trial.

Interim analyses and premature termination of the study {#s2q}
-------------------------------------------------------

The IDMB can also recommend to stop the trial early for ethical reasons if one of the groups clearly shows evidence of a significant benefit. An interim analysis will be performed on the primary endpoint when 50% of patients have been randomised and discharged from hospital. The interim analysis will be performed by the IDMB, who will report to the SC.

The Haybittle--Peto boundary approach will be used. If the interim analysis shows a probability of ≤0.001 that a difference as extreme between the treatments is found, given that the null hypothesis is true, then the trial will be stopped early.

Centres {#s2r}
-------

The trial will start in two centres (University of Debrecen and University of Pécs), after which the study is open for other centres. In all cases the IDMB will make an audit of the centre and will report to the SC. The SC has the right to decide whether the centre meets the required quality to join the study. Compulsory requirements for a centre are: (1) it needs to treat at least 50 patients with AP a year; (2) it needs to have all the equipment required for the study; (3) besides the regular medical team, the centre has to appoint at least one doctor and one nurse/administrator fully available for the trial with no additional commitments which can interfere with her/his duty when her/his availability is required; (4) the blinding described above can be fully utilised; (5) all persons need to attend a preliminary meeting where all the details concerning the studies are discussed fully and have qualified as investigators in a GCP course. Centres wishing to join need to send a letter of intent to the corresponding author by email.

Publication policy {#s2s}
------------------

Centres providing more than 25 patients can provide two authors to the authorship list. Every additional 25 patients will give the opportunity to nominate an additional author.

Feasibility {#s2t}
-----------

As a general protocol for the treatment of AP at the Centre for Translational Medicine at the University of Pécs, patients with AP receive early EN (using a NG tube). Patients receive 50 mL Nutrison Energy per hour starting immediately when they arrive to the ward from the Emergency Department. Patient data between the period 1 January 2016 to 31 May 2016 were analysed and the following observations were noted. (1) In 85% of all AP admissions early EN could have been started within 24 hours; in 15% of cases it was not achievable due to delayed transfer to the ward or vomiting. In these cases, patients received a NG tube later or they received a NJ tube whenever X-ray assistance was available. (2) Around 80% of NG-fed patients tolerated NG feeding without any complications. For the rest of the patients who had gastric retention or vomiting, NG feeding was stopped and they received a NJ tube whenever X-ray assistance was available. (3) Comparing the outcome (rate of severity, mortality, necrosis, intervention, etc) of this treatment protocol with the nil per os protocol used in most Hungarian hospitals showed that patients enjoyed benefits with no risk of early enteral feeding, which data confirm the literature described in the introduction. About 250 patients at the University of Pécs and about 150 patients at the University of Debrecen are admitted annually. Therefore, if no other institution joins the study, it can be completed within 3 years.

Safety {#s2u}
------

Since no unknown drugs/therapy are used in the study, no adverse or serious adverse events are expected/interpretable that would be attributable to the intervention during the trial. In this trial the IDMB will examine safety variables after every 16 patients have completed. Moreover, investigators will report adverse or serious adverse events on a separate form which has to be sent to the IDMB and SC. The SC will discuss and, if the adverse effect is confirmed, it will be reported to the relevant institutional and national ethical committee (<http://www.ett.hu/tukeb.htm>).

Additional information and future plan {#s2v}
--------------------------------------

Blood samples (serum and plasma) from all patients will be stored in order to study laboratory parameters later if required (eg, the laboratory could not measure it), and in order to build up a biobank for later clinical studies to which all participants will be given informed consent. The samples will be stored at −80°C. A follow-up study (called GOULASH PLUS) is under preparation in order to follow the patients for up to 5 years after the study. The study protocol will also be published.

Discussion {#s3}
==========

Here we report the protocol of a prospective double-blind randomised controlled trial to study the effects of early energy restoration in AP. The preclinical studies[@R1] and meta-analyses suggest that early energy supplementation should be beneficial. Our main hypothesis is that elevating the energy level of acinar and ductal cells will prevent these cells from injury, therefore decreasing the extent of necrosis during AP. Since both the local and systemic complications (immune response) largely depend on the extent of the necrosis, we propose that this intervention will reduce multiorgan failure and mortality in AP as well. Although nutritional interventions for patients with mild pancreatitis are probably not needed, we must involve all patients with AP in the study. It has to be highlighted that the main aim of the study is not to find new treatments for MAP or SAP but to prevent the development of SAP. This is the reason why severity cannot be a selection criterion but has to be the primary endpoint. Concerning ethical issues, this study has very low risk for patients. The enteral solution (Nutrison Energy) used in this study is widely used in several diseases related to malnutrition in patients and has almost no contraindications, therefore no adverse events are expected during the trial.

Ethics and dissemination {#s4}
========================

The trial is registered at the ISRCTN registry (ISRCTN63827758) and received relevant ethical approval with the reference number 55961-2/2016/EKU issued by the Scientific and Research Ethics Committee of the Medical Research Council. At the end of the project we will disseminate our results to the medical community and will publish our results via open access.

Conclusion {#s5}
==========

This study provides the first type A evidence concerning the necessity of energy intake for patients with AP. This protocol is the first version of the trial completed on 24 May 2017.
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